COLL - Collegium Pharmaceutical Inc

COLL - Collegium Pharmaceutical Inc

https://www.collegiumpharma.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Collegium to Participate in Upcoming Investor Conferences - Collegium Pharmaceutical ( NASDAQ:COLL )

Benzinga • 2 weeks, 4 days ago • score: 0.39

STOUGHTON, Mass., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Collegium Pharmaceutical, Inc. COLL today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025 Boston, MA

Director Of Collegium Pharmaceutical Sold $400K In Stock - Collegium Pharmaceutical ( NASDAQ:COLL )

Benzinga • 1 month ago • score: 0.18

On August 12, a recent SEC filing unveiled that John G. Freund MD, Director at Collegium Pharmaceutical COLL made an insider sell. What Happened: MD's decision to sell 11,659 shares of Collegium Pharmaceutical was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on ...

Collegium Pharmaceutical ( COLL ) Q2 Earnings and Revenues Surpass Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.17

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +3.70% and +4.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing Collegium Pharmaceutical ( COLL ) Right Now?

Zacks Commentary • 1 month, 3 weeks ago • score: 0.47

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

John G. Freund MD At Collegium Pharmaceutical Decides to Exercises Options Worth $243K - Collegium Pharmaceutical ( NASDAQ:COLL )

Benzinga • 3 months ago • score: 0.13

A significant insider transaction involving the exercise of company stock options was reported on June 11, by John G. Freund MD, Director at Collegium Pharmaceutical COLL, as per the latest SEC filing. What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.

52W High

$42.29

52W Low

$23.23

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.63

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

36.15

Forward P/E (<15 better)

5.35

EV/EBITDA (<8 favorable)

5.23

EV/Revenue (<3 favorable)

2.57

P/S (TTM) (<3 favorable)

1.71

P/B (<3 favorable)

5.20

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.72%

Institutions (25–75% balanced)

116.55%

Shares Outstanding

31,502,100

Float

28,098,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

707,007,000

Gross Profit (TTM)

618,708,000

EPS (TTM)

1.06

Profit Margin (>10% good)

0.05%

Operating Margin (TTM) (higher better)

0.20%

ROE (TTM) (>15% strong)

0.16%

EPS YoY (Quarterly) (>10% good)

-0.34

Revenue YoY (Quarterly) (>8% good)

0.29

Momentum

Bearish momentum

Value

0.9557

Previous

1.1595

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025